Nurix Therapeutics Begins Pivotal Phase 3 Trial Testing Novel Leukemia Treatment Against Key Competitor

San Francisco, Tuesday, 4 August 2026.
On August 4, 2026, Nurix Therapeutics enrolled the first patient in a Phase 3 trial evaluating its targeted protein degrader, bexobrutideg, head-to-head against Eli Lilly’s pirtobrutinib for chronic leukemia.